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Abstract. 
 
Mutations in the corniﬁed cell envelope pro-
tein loricrin have been reported recently in some pa-
tients with Vohwinkel syndrome (VS) and progressive
symmetric erythrokeratoderma (PSEK). To establish a
causative relationship between loricrin mutations and
these diseases, we have generated transgenic mice ex-
pressing a COOH-terminal truncated form of loricrin
that is similar to the protein expressed in VS and PSEK
patients. At birth, transgenic mice (ML.VS) exhibited
erythrokeratoderma with an epidermal barrier dysfunc-
 
tion. 4 d after birth,
 
 
 
high-expressing transgenic animals
 
showed a generalized scaling of the skin, as well as
 
a constricting band encircling the tail and, by day 7,
a thickening of the footpads. Histologically, ML.VS
transgenic mice also showed retention of nuclei in the
stratum corneum, a characteristic feature of VS and
PSEK. Immunoﬂuorescence and immunoelectron mi-
croscopy showed the mutant loricrin protein in the nu-
cleus and cytoplasm of epidermal keratinocytes, but did
not detect the protein in the corniﬁed cell envelope.
Transfection experiments indicated that the COOH-
terminal domain of the mutant loricrin contains a nu-
clear localization signal. To determine whether the
ML.VS phenotype resulted from dominant-negative in-
terference of the transgene with endogenous loricrin,
we mated the ML.VS transgenics with loricrin knock-
out mice. A severe phenotype was observed in mice
that lacked expression of wild-type loricrin. Since lori-
crin knockout mice are largely asymptomatic (Koch,
P.K., P.A. de Viragh, E. Scharer, D. Bundman, M.A. Long-
ley, J. Bickenbach, Y. Kawachi, Y. Suga, Z. Zhou, M. Hu-
 
ber, et al., 
 
J. Cell Biol.
 
 151:389–400, this issue), this phe-
notype may be attributed to expression of the mutant
form of loricrin. Thus, deposition of the mutant protein
in the nucleus appears to interfere with late stages of
epidermal differentiation, resulting in a VS-like pheno-
type.
Key words: loricrin • transgenic • erythrokerato-
derma • Vohwinkel’s syndrome
 
Introduction
 
The formation of the cornified cell envelope (CE)
 
1
 
 in ter-
minally differentiating keratinocytes is generally accepted
to be crucial for the barrier function of the skin (Roop,
1995). The CE represents an insoluble layer of
 
 
 
proteins
(e.g., involucrin, loricrin, small proline-rich proteins
[SPRRs], elafin, cystatin A, S100 family proteins, and
some desmosomal proteins) that are covalently cross-
linked by 
 
e
 
-(
 
g
 
-glutamyl)lysine
 
 
 
isopeptide bonds formed by
epidermal transglutaminases (TGases) (Steven and Stein-
ert, 1994; Steinert and Marekov, 1995).
Loricrin is expressed late in epidermal differentiation
and is
 
 
 
the major component of the CE, constituting as
much as 70% of its mass (Steven and Steinert, 1994). Lori-
crin is a glycine-, serine-, and cysteine-rich basic protein
expressed in the granular cell layer of the epidermis (Meh-
rel et al., 1990; Hohl et al., 1991), where it is first stored in
aggregates (L granules) that are predominantly cytoplas-
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2
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PSEK, progressive symmetric erythrokeratoderma; RPA, RNase protec-
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mic, but occasionally are seen in the nucleus (Steven et al.,
1990; Ishida-Yamamoto et al., 1993). In the last stage of
terminal differentiation, these aggregates are dispersed
and loricrin is assembled into the CE where it is cross-
linked with the other CE components (Steven et al., 1990).
Recently, a mutation in the loricrin gene has been re-
ported in certain subtypes of Vohwinkel syndrome (VS)
(Online Mendelian Inheritance in Man [OMIM™] no.
124500, available at http://www.ncbi.nlm.nih.gov/Omim/)
(Maestrini et al., 1996; Korge et al., 1997; Armstrong et al.,
1998; Takahashi et al., 1999). This was one of the first ge-
netic disorders reported affecting a CE component and
the first to be associated with a gene in the epidermal dif-
ferentiation complex on chromosome 1q21 (Maestrini et
al., 1996). Furthermore, Ishida-Yamamoto et al. (1997)
identified a similar loricrin mutation in a family with pro-
gressive symmetric erythrokeratoderma (PSEK). In the
cases reported to date, frameshift mutations in the loricrin
gene (due to a single base pair insertion at codon 231
[231insG] or codon 209 [209insT] in VS, or at codon 224
[224insC] in PSEK) have produced mutant forms of lori-
crin with altered and extended COOH termini, in conse-
quence of alternative, downstream termination signals.
Thus, the common feature of
 
 
 
all VS-related loricrin muta-
tions described to date is replacement of the COOH-ter-
minal Gly- and Gln/Lys-rich domain with highly charged
Arg- and Leu-rich amino
 
 
 
acid
 
 
 
sequences.
VS is characterized by a diffuse thickening of the epider-
mis of palms and soles (palmoplantar hyperkeratosis) with
small “honeycomb” depressions and progressive forma-
tion of constrictions on
 
 
 
digits and toes (pseudoainhum)
(Vohwinkel, 1929; Gibbs and Frank, 1996). Irregularly
shaped thickening of the skin (keratosis) is also seen
 
 
 
on
the backs of hands and feet, on the knees, and on the el-
bows. Some VS families also exhibit deafness, whereas
others have normal hearing but develop a diffuse congeni-
tal ichthyosis (Camisa and Rossana, 1984). On the basis of
recent molecular studies, it is now clear that VS associated
with deafness is genetically distinct and caused by muta-
tions in connexin 26 (Maestrini et al., 1999), whereas VS
associated with ichthyosis is caused by mutations in lori-
crin (Maestrini et al., 1996; Korge et al., 1997; Armstrong
et al., 1998; Takahashi et al., 1999). The PSEK family ex-
amined by Ishida-Yamamoto et al. (1997) exhibited wide-
spread erythematous keratotic plaques and palmoplantar
hyperkeratosis with pseudoainhum. The clinical differ-
ences between VS associated with ichthyosis and PSEK
were thought to be due to the insertion site of the muta-
tion. However, it remains to be seen whether the site of
mutation will consistently correlate with the respective
disease phenotype.
Here, we introduced a transgene into the germline of
mice
 
 
 
that mimics the loricrin mutations identified previ-
ously in VS patients. Transgenic mice expressing this mu-
tant form of loricrin exhibited an erythematous skin phe-
notype at birth, with a thickening of the epidermis
(erythrokeratoderma). Mice expressing the highest levels of
the transgene also showed a pseudoainhum-like constrict-
ing band around their tail and hyperkeratosis of the foot-
pads around day 7. Thus, these animals represent a new
model system which will be useful to study the pathogenesis
and potential treatments of human loricrin keratoderma.
 
Materials and Methods
 
Construction of the ML.VS Transgene and Generation 
of Transgenic Mice
 
We engineered a single nucleotide insertion (C) at position 1190 (codon
372) of the mouse loricrin coding sequence (numbering is according to
Mehrel et al., 1990; sequence data available from EMBL/GenBank/DDBJ
under accession no. M34398) using PCR-mediated mutagenesis to mimic
the mutation found in the families with VS. This point mutation resulted
in the generation of an additional Acc65I restriction enzyme site in codon
371 and 372 (position 1186–1191).
A BamHI–PstI fragment of the mouse loricrin genomic DNA (DiSepio
et al., 1995) spanning positions 779–1684 was cloned into the pGem3zf(
 
1
 
)
vector (Promega) and used as a PCR template. Overlapping PCR prod-
ucts, including positions 779–1203 and positions 1181–1684,
 
 
 
were amplified
using T7 and Sp6 primers as well as the loricrin-specific primers, oligonu-
cleotide 1 (5
 
9
 
-CCACCTCCACAGGGTACCACCTCC-3
 
9
 
) and oligonu-
cleotide 2 (5
 
9
 
-GGAGGTGGTACCCTGTGGAGGTGG-3
 
9
 
), both of
which include an additional Acc65I site in the sequence (underlined). The
PCR products amplified with primers T7/oligonucleotide 1 and oligonucle-
otide 2/Sp6 were subcloned into the pGemT vector (Promega) and se-
quenced. These 5
 
9
 
 and 3
 
9
 
 mutant DNA fragments were then combined us-
ing the Acc65I restriction enzyme site, resulting in a mutated loricrin
construct with
 
 
 
a C insertion at nucleotide position 1190 (pGemT1190insC).
A BamHI–Bsu36I fragment from pGemT1190insC containing the point
mutation was then inserted into the 6.5-kb genomic loricrin fragment, re-
placing the corresponding wild-type sequence. This construct (ML.VS, see
Fig. 1) was injected into ICR mouse embryos to produce transgenic mice
expressing the mutant loricrin (DiSepio
 
 
 
et al., 1995).
Transgenic mice were identified by PCR using tail DNA as a template
with oligonucleotide 3 (3
 
9
 
-TCCTCTCAGCAGACCAGTCAGACCT-5
 
9
 
)
and oligonucleotide 4 (3
 
9
 
-CTCTTCCAGCTCTGTTGTCTCCGTT-5
 
9
 
),
which gave after Acc65I restriction enzyme digestion, a 440-bp band in non-
transgenic pups, but 440- and 385-bp bands in transgenics. PCR was per-
formed with 200 ng of genomic DNA using an initial denaturation at 94
 
8
 
C
(5 min); followed by 25 cycles with denaturation
 
 
 
at 94
 
8
 
C
 
 
 
(1 min),
 
 
 
annealing
at 55
 
8
 
C (2 min), and elongation at 72
 
8
 
C (3 min); and, finally, 15 min at 72
 
8
 
C.
 
Histology and Immunofluorescence Microscopy
 
All samples were from the back skin of severely affected F2 transgenics
and nontransgenic littermates. Tissues were fixed in Carnoy’s solution
(chloroform/acetic acid/ethanol, 3:1:6 [vol/vol/vol]) at 4
 
8
 
C overnight, trans-
ferred to 95% ethanol, embedded in paraffin, sectioned, and stained with
hematoxylin and eosin. Biopsy samples were frozen in OCT (Tissue-TekII;
Lab-Tek Products) at 
 
2
 
70
 
8
 
C, sectioned at 4–6 
 
m
 
m, and mounted onto glass
slides. For immunofluorescence microscopy, the following antibodies were
used: guinea pig antibodies to the COOH terminus
 
 
 
of loricrin (LorCAb),
which were produced against the synthetic peptide CHQTQQKQAPTW-
PCK (Mehrel et al., 1990); keratin 14 (K14) antibodies (Roop et al., 1984);
rabbit antibodies directed to the NH
 
2
 
 
 
terminus of loricrin (LorNAb),
which were produced against the synthetic peptide SHQKKQPTPCP-
PVGCGKTSG; and antibodies to K6 (Roop et al., 1984). The following
secondary antibodies were used: biotinylated goat anti–guinea pig (Vector
Laboratories), sheep anti–rabbit conjugated with FITC (Dako), and
Streptavidin–Texas red (GIBCO BRL). Double label immunofluores-
cence was performed as described previously (Roop et al., 1987).
 
Ultrastructural Analysis
 
Skin samples were processed essentially as described previously (Jarnik et
al., 1996). In brief, back skin biopsies (
 
z
 
1 mm
 
3
 
) were briefly washed in
PBS and fixed for 3 h with three changes in 2% glutaraldehyde in 50 mM
cacodylate buffer, pH 7.2, containing 2% sucrose; washed with the same
buffer without sucrose; and postfixed two times for 1 h. with 1% osmium
tetroxide. After an overnight wash in water, samples were serially dehy-
drated in ethanol and propylenoxide, infiltrated with EMbed-812 resin
(EMS), and polymerized for 24 h at 65
 
8
 
C. Thin sections were stained with
2% uranyl acetate and lead citrate.
For immunocytochemistry, frozen specimens were prepared according
to Tokuyasu (1980). The tissue was fixed in 6% formaldehyde in 0.1 M
Pipes, pH 7.05; washed with the same buffer; perfused with 2.1 M sucrose;
placed on the specimen carrier; and quenched in liquid nitrogen. Thin cryo-
sections were cut, transferred to a drop of 2.3 M sucrose, and mounted on 
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formvar/carbon-coated grids. The immunostaining procedures have been
described elsewhere (Steven et al., 1990; Jarnik et al., 1996). The primary
antibody for immunocytochemistry was LorNAb, and the secondary label
was a protein A–10-nm gold complex (BBInternational).
The specimens were viewed on a ZEISS 902 electron microscope.
 
Bromodeoxyuridine Labeling Experiments
 
Age-matched transgenic and normal samples were processed as described
previously (Dominey et al., 1993). In brief, newborn transgenic and con-
trol mice were injected i.p. with 250 mg/kg body weight bromodeoxyuri-
dine (BrdU) in 0.9% NaCl (Sigma-Aldrich) and killed after 1 h. Dorsal
skin was fixed in 70% ethanol at 4
 
8
 
C, embedded in paraffin, and sec-
tioned. Sections were cut, deparaffinized, and soaked in 2 N HCl for 30
min. Sections were rehydrated and dried, and treated with undiluted
FITC-conjugated mAb to BrdU (Becton Dickinson) mixed with guinea
pig antiserum to mouse K14 for 20 h
 
 
 
(Dominey et al.,
 
 
 
1993).
 
Construction of Enhanced Green Fluorescent Protein 
Vectors and Green Fluorescent Protein Assay in
HeLa Cells
 
A eukaryotic expression vector with an enhanced green fluorescent pro-
tein (EGFP) sequence and multicloning sites was used for this assay
(pEGFP-C1; CLONTECH Laboratories, Inc.). In brief, various sequences
from the COOH terminus of mutant loricrin were fused to the 3
 
9
 
 end of
the GFP tag in order to identify potential nuclear localization signal
(NLS). 900-bp BamHI–PstI fragments from both the wild-type and the
ML.VS mutant loricrin sequence were subcloned into pE6FP-C1 to create
GFP(ML BamHI/PstI) and GFP(ML.VS BamHI/PstI) (see Fig. 11). Fur-
Figure 1. Construction of transgene. Schematic representation of
the structures of the ML.VS transgene and the 6.5-kb mouse ge-
nomic DNA construct. We introduced a frameshift mutation re-
sulting in a delayed termination of translation (black box) into the
second exon (white boxes) of the loricrin gene by inserting a cy-
tosine (C) at position 1190 (arrowhead). An additional Acc65I site
was created by the mutation (underlined).
Figure 2. Macroscopic pheno-
types of ML.VS transgenic mice.
(a) Severely (left) and moder-
ately (middle) affected trans-
genic neonates, and control
(right) littermate F2 pups. Note
the erythrokeratoderma with a
shiny skin in the transgenic pups.
(b) Phenotype of a pup at day 4
after birth. Note the hyperkera-
totic, scaly skin, which resembles
generalized ichthyosis. (c) Se-
verely affected transgenic mice
exhibited hyperkeratotic skin
limited to buttocks and tails at
day 5 after birth. (d) Hyperkera-
totic constricting bands develop
at the base of tail at day 7. Note
that the distal part of the tail was
slightly edematous. (e and f)
Front and rear paws of transgen-
ics at day 10. Note the severe
scaling of the footpads. 
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thermore, a 490-bp Acc65I–PstI subfragment from the mutant loricrin se-
quences was fused to the GFP sequence to create GFP(ML.VS Acc65I/
PstI). Four potential NLS were amplified by PCR using GFP(ML.VS
Acc651/PstI) as a template
 
 
 
and fused to the GFP tag. After PCR amplifi-
cation, the four PCR fragments were sequenced, digested
 
 
 
with NheI and
BamHI, and cloned into the pEGFPC-1 vector, resulting in plasmids
GFP(NLS1), GFP(NLS2), GFP(NLS3), and GFP(NLS4). Oligo 3, 5
 
9
 
-GTG-
AACCGTCAGATCCGCTA-3
 
9
 
 was complementary to
 
 
 
the 5
 
9
 
 end of
the GFP tag in plasmid GFP(ML.VS Acc65I/PstI); Oligo 4,
 
 
 
5
 
9
 
-
ATATATGGATCCCCGCCGCCTCCGGGTACCGTCGACAGAAT-
3
 
9
 
 was specific for NLS1; Oligo 6, 5
 
9
 
-ATATATGGATCCCCGCCT-
CCGCCTCCGGGTACCGTCGACTGCAGAAT-3
 
9
 
 was specific
 
 
 
for
NLS3; Oligo 5, 5
 
9
 
-ATATATGGATCCCCTCCGCAGCCACCGCCGG-
GTACCGTCGACTGCAGAAT-3
 
9 
 
was specific for NLS2; Oligo 4, 5
 
9
 
-
ATATATGGATCCCCTCCTCCGCAGCCACCGCCGCTGCCTCCGG-
AAGAGCCACCTC CGGGTACCGTCGACTGCAGAAT-3
 
9
 
 was spe-
cific
 
 
 
for NLS4. The BamHI site used in the cloning procedure is under-
lined. The NheI site used is at position 592 of pE6 FPC1.
The constructs were transfected into HeLa cells using the LT1
polyamine reagent (Mirus; PanVera) according to the method recom-
mended by the supplier. HeLa cells were grown at 37
 
8
 
C, 5% CO
 
2
 
, in OPTI-
MEM medium (GIBCO BRL) supplemented with 4% FBS, 100 U/ml pen-
icillin G, and 0.1 mg/ml streptomycin sulfate.
 
Quantitation of Transgene Expression by RNase 
Protection Assay 
 
RNA from neonatal epidermis was isolated using RNazol B (Tel-Test,
Inc.), according to standard protocols. In brief, separated epidermis was
frozen in liquid nitrogen, ground to a powder, and mixed with RNazol B.
The resulting
 
 
 
slurry was mixed with chloroform (10:1). Samples were centri-
fuged, the upper aqueous layer was removed, and RNA was precipitated
with ethanol. RNA was then pelleted by centrifugation and resuspended in
50 
 
m
 
l of 1 
 
m
 
M EDTA. RNase protection assay (RPA) was performed using
the RNase II kit (Ambion, Inc.), according to the supplied protocol. To ac-
 
curately quantitate expression levels of the mutant loricrin transgenes rela-
tive to the expression of endogenous loricrin, a 375-nucleotide antisense
probe was used for RPA that corresponded to the 3
 
9
 
 end of the mutant lori-
crin coding sequence.
 
 
 
The 375-nucleotide
 
 
 
probe was designed to be fully
protected by the mutant loricrin transcripts, whereas wild-type transcripts
would protect a sequence of only 350 nucleotides. RPA samples were run
on a 6% acrylamide/8 M urea TBE gel followed by autoradiography and
quantitation using a densitometer (Quick Scan Jr.; Helena Laboratories).
All RPAs were performed using a glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) probe as an internal control for total RNA quantity.
 
Detecting a Barrier Dysfunction in Transgenic Mice
 
Transepidermal water loss (TEWL) from the ventral skins of neonatal
mice was examined using a Tewameter TM210 (Courage and Khazaka), as
described previously (Matsuki et al., 1998) (see Fig. 9 a).
We also used a simple dye penetration test to demonstrate barrier dys-
function in transgenic mice (Matsuki et al., 1998).
 
 
 
The backs of neonatal
mice were immersed in 1 mM Lucifer yellow in PBS (Fluka Chemical Co.).
After 1 h of incubation, mice were killed, then frozen, and dorsoventrally
sliced at a thickness of 5 
 
m
 
m. The sections were analyzed using fluores-
cence microscopy (see Fig. 9 b).
 
Results
 
Construction of the ML.VS Transgene and 
Generation of Transgenic Mice Expressing 
the VS Loricrin Mutation
 
To construct the ML.VS transgene, we inserted a cytosine
residue at position 1190 of the loricrin coding sequence
(1190insC). This point mutation results in a frameshift, which
replaces the 86 COOH-terminal amino acids with missense
amino acids (Fig. 1, schematic representation of vector con-
struction and comparison of mutant and wild-type loricrin se-
quence). Furthermore, due to this frameshift mutation,
 
 
 
the
endogenous termination codon is not recognized,
 
 
 
thereby ex-
tending the loricrin polypeptide by
 
 
 
22 amino acids.
10 ML.VS loricrin transgenic mice were identified by PCR
analysis of their tail DNAs. Of these, three independently de-
rived transgenic animals were bred separately to generate F1
offspring. All F1 mice that carried the transgene displayed
similar phenotypic abnormalities that were inheritable, indi-
cating that these aberrations could clearly be attributed to
transgene expression rather than the transgene integration
sites. One founder line, which contained three copies of the
transgene, was selected for detailed analysis.
Figure 3. RPAs using RNA
from neonatal epidermis.
Note the higher expression
level of mutant (MT) loricrin
transcripts in the severely af-
fected homozygous F2 pups
(MLVS homo) compared
with the moderately affected
heterozygous F2 pups (MLVS
hetero). Simultaneous detec-
tion of endogenous wild-type
(WT) loricrin transcripts pro-
vides a loading control.
Figure 4. Immunofluorescence analysis to detect the VS mutant protein. (a and b) Double-immunofluorescent microscopy with Lor-
NAb (FITC) and LorCAb (Texas red) antibodies. LorNAb detects expression of both endogenous and transgenic epitopes, whereas
the LorCAb only detects endogenous epitopes. The LorNAb revealed a markedly strong and broad expression in ML.VS transgenics
(a) compared with nontransgenics (b). The LorNAb (FITC) also detected immunoreactive granules within the nuclei in the suprabasal
layers of ML.VS transgenics (a, arrowheads). Dots mark the dermo–epidermal interface. (c) Nuclear accumulation of the VS mutant
protein is more apparent in ML.VS/Lor2/2 neonatal skin (see below) stained with LorNAb and DAPI.  
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All transgenic F1 pups from this founder had shiny skin
when they were born, similar to that exhibited by the mod-
erate F2 pup shown in Fig. 2 a (middle). They usually de-
veloped small scales over the whole body (ichthyosis)
within the first 3 d of life (Fig. 2 b), which is consistent with
ubiquitous epidermal expression of the
 
 
 
loricrin transgene.
The clinical appearance of this mouse phenotype is similar
to that reported previously for a patient with VS associ-
ated with ichthyosis (Camisa and Rossana, 1984). How-
ever, the transgenic skin phenotype gradually disappeared
and was absent in adult animals.
Since the human disease is inherited in an autosomal
dominant fashion, we assume that the mutant and normal
alleles are expressed at comparable levels. In an attempt
to determine the phenotypic consequences of increasing
the expression level of the mutant gene in the mouse
model, we generated animals that were homozygous for
the transgene in F2. Homozygous F2 pups exhibited se-
vere neonatal erythrokeratoderma with red, shiny, and
taut skin (Fig. 2 a, left).
To verify that phenotype severity correlated with the
level of transgene expression, we isolated RNA from the
epidermis of F2 neonates and performed RPA. The RPA
probe was designed to detect both wild-type and trans-
gene-derived (mutant) loricrin transcripts (see Materials
 
and Methods).
 
 
 
The transgene expression levels were in-
creased approximately twofold in the severely affected F2
pups compared with moderate heterozygotes (Fig. 3).
Thus, phenotype severity correlated with the expression
levels of the transgene.
To examine the expression pattern of ML.VS loricrin in
the epidermis of transgenic animals, we performed immu-
nofluorescence microscopy
 
 
 
using antibodies specific for
epitopes located on either the NH
 
2
 
 (LorNAb) or COOH
(LorCAb) terminus (Fig. 4). Expression of both the trans-
gene and wild-type loricrin was only detected with Lor-
NAb, since the ML.VS protein does not have the epitope
recognized by LorCAb. Interestingly, granules immunore-
active with LorNAb were frequently observed within the
nuclei of suprabasal keratinocytes of ML.VS transgenics
(Fig. 4, a and c).
 
 
 
Since these granules were not stained with
LorCAb, which detects the endogenous loricrin protein,
this staining pattern appears to result from accumulation
of the mutant form of loricrin in the nucleus (see below).
Severely affected homozygous transgenic mice also devel-
oped additional phenotypes 
 
z
 
5 d after birth: a thickening of
the epidermis around the buttocks, the base of the tail, and
in the footpads (see Figs. 2, c, e, and f). At around day 7,
transgenic mice showed a constricting band at the base of
the tail (Fig. 2 d), similar to that seen around the digits of VS
Figure 5. Histological analysis of
ML.VS transgenic mice. Hematoxy-
lin and eosin–stained paraffin sec-
tions of dorsal skin from transgenic
(a) and nontransgenic mice (b).
Note the remnants of nuclei present
in the stratum corneum  of trans-
genic skin (arrows). (c) Hyperkera-
tosis and parakeratosis were evi-
dent in the cornified cell layers
around the constricting band in the
transgenic tail. (d) Higher magnifi-
cation of the cornified layers reveals
the retention of nuclei (arrows). (e)
Control tail. (f) Hyperkeratosis and
parakeratosis were also evident in
the transgenic footpad. (g) Higher
magnification of f to demonstrate
retention of nuclei (arrows). 
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patients. The distal part of the constriction
 
 
 
was usually
slightly edematous because of the constriction. However,
autoamputation, which is observed in VS patients, was not
observed in homozygous pups and the phenotype
 
 
 
became
less severe and gradually disappeared after day 11 (data not
shown). Similarly, hyperkeratosis of the footpads also be-
came less evident after day 11 (data not shown). Although
the ML.VS transgene was expressed in other tissues, such as
tongue, esophagus, and forestomach, we were unable to de-
tect an obvious phenotype in these tissues (data not shown).
 
Histopathology of ML.VS Transgenics
 
Histology of neonatal dorsal skin in homozygous transgen-
ics showed parakeratosis, characterized by retention of nu-
clei in the stratum corneum
 
 
 
(Fig. 5 a, arrowheads). Though
the erythrokeratoderma phenotype suggested hyperkerato-
sis of the skin, thickening of the epidermis was not very pro-
nounced in
 
 
 
newborn transgenics. However, biopsies from
the region of the constricted tail and footpads showed se-
vere hyperkeratosis (Fig. 5, c and f). In addition, parakerato-
sis was much more evident in these biopsies (Fig. 5, d and g).
Figure 6. Ultrastructure of transgenic skin. Electron micrograph of a thin section through the upper epidermis from back skin of a
transgenic ML.VS mouse. No gross morphological abnormalities in CE formation are evident in the transgenics, but parakeratotic nu-
clei are observed in the transitional layer (arrows). Moreover, in the nuclei of granular layer cells, electron-dense granules are visible
(arrowheads, bottom right, in the enlargement of boxed area) that are not seen in normal siblings. Bars, 0.5 mm.
 
Figure 7.
 
Immunoelectron microscopy of transgenic ML.VS mouse skin. Immunogold labeling was performed with LorNAb antibodies
and 10-nm gold particles applied to sections of dorsal skin from biopsy samples, prepared according to the method of Tokuyasu (1980).
Abnormal granular aggregates observed within parakeratotic corneocyte nuclei (a and b) and granulocyte nuclei (c) labeled positively
with LorNAb. The aggregates have a somewhat different visual texture in these preparations compared with Epon embeddings (see
Fig. 6). Note that these aggregates (arrows in a and c) do not colocalize with nucleoli. Nu, nucleus; No, nucleolus; Cy, cytoplasm. In con-
trast, with this antibody, normal skin shows diffuse cytoplasmic staining as well as staining of round L granules in the cytoplasm and nu-
cleus (data not shown, see Steven et al., 1990; Jarnik et al., 1996). Positive labeling of the CE was observed for Lor
 
1
 
/
 
1
 
 transgenics (a),
but not for Lor
 
2
 
/
 
2
 
 transgenics (c). These observations imply that for the former mice, the antibody is labeling wild-type loricrin in the
cell envelope and the mutant loricrin in the intranuclear aggregates (see Results). In parakeratotic nuclei, we observe characteristic
crescent-shaped features of low electron density (a and b, white arrowheads). Their origin is unclear but, to date, we have observed
them only in parakeratotic nuclei and in Epon embeddings (data not shown) as well as in Tokuyasu preparations. Bar, 0.5 
 
m
 
m. 
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At the light microscopy level, the only striking morpho-
logical abnormality in ML.VS transgenics was the parakera-
tosis in the cornified layers. Ultrastructurally, the granular,
transitional, and cornified cell layers were slightly thicker
than in normal epidermis, but keratohyalin granules ap-
peared to be of the usual size and numbers. The most strik-
ing abnormalities were the presence of parakeratotic nuclei
in the stratum corneum (Fig. 6, arrows) and of intranuclear
condensates of moderate to high electron density in the up-
per granular cell layers (Fig. 6, arrowheads, bottom right).
Immunoelectron microscopy showed that these conden-
sates were recognized by LorNAb in both parakeratotic
corneocyte nuclei (Figs. 7, a, arrows, and c) and granulocyte
nuclei (Fig. 7 c, arrows). As expected, the CE labeled posi-
tively with LorNAb in ML.VS transgenic epidermis (Fig. 7
a) as well as in control epidermis (data not shown).
To assess potential changes in the proliferative compart-
ment of phenotypic epidermis, control and severely af-
fected newborn mice were labeled with BrdU for 1 h be-
fore killing. Staining with an anti-BrdU antibody showed
an increase in mitotically active cells in transgenic epider-
mis (Fig. 8 a) over controls (Fig. 8 b). Transgenic epidermis
had 60.5 6 10.6 labeled nuclei/mm, whereas control epider-
mis had 32.2 6 5.8 labeled nuclei/mm. The strong interfol-
licular induction of K6 in the acanthotic epidermis at the
tail constriction (Fig. 8 c) and the epidermis of hyperkera-
totic footpads (data not shown) was also consistent with hy-
perproliferation. As expected, K6 expression was restricted
to the hair follicles in normal control littermates (Fig. 8 d).
ML.VS Mice Exhibit a Defect in Epidermal
Barrier Function
The observation of dry, scaly skin suggested that ML.VS
pups suffered from dehydration due to an epidermal bar-
rier dysfunction. To examine this possibility, TEWL of
ML.VS skin was assessed with an evapometer. TEWL was
Figure 8. Increased BrdU labeling and interfollicular K6 ex-
pression in ML.VS transgenic epidermis. BrdU incorporation
analysis was used to compare the distribution of S phase nuclei.
BrdU labeling (yellow) of transgenic skin (a) shows an increase
in mitotic activity versus control (b). Note the additional la-
beled nuclei in the basal layer in transgenic epidermis. The sec-
tions were also double-labeled with K14 (red). Marked interfol-
licular staining with an antibody to K6 (FITC) is evident in
transgenic epidermis (c) compared with control (d). The epi-
dermis was counterstained with antibody to K14 (Texas red).
Yellow indicates colocalization at K14 and K6. In both cases,
hair follicles stain positive for K6. Note strong interfollicular
expression of K6 in transgenic tail from mice at day 7 after birth
in addition to the staining of cells in the outer root sheaths.
Figure 9. Defects in the skin barrier function of ML.VS transgenic mice. (a) TEWL was measured in transgenics and normal litter-
mates. Note TEWL was increased more than fourfold in severely affected mice. Error bars represent SEM. Normal (N), n = 20; moder-
ate (M), n = 24; severe (S), n = 12. (b and c) The fluorescent micrographs show the distribution of Lucifer yellow in the skin from se-
verely affected (b) and control mice (c).Suga et al. Transgenic Mice Expressing Mutant Loricrin 409
increased more than twofold and fourfold in moderately
and severely affected transgenics, respectively (Fig. 9 a).
As an alternative method to evaluate epidermal barrier
dysfunction, we examined the diffusion of the fluorescent
dye Lucifer yellow through the epidermis (Matsuki et al.,
1998). The dye was found to be retained in the upper lay-
ers of the stratum corneum in control neonatal mice (Fig. 9
c). In contrast, in severely affected transgenic pups, the
dye penetrated significantly deeper into the epidermis
(Fig. 9 b).
Introduction of the ML.VS Transgene into Loricrin 
Null Mice (ML.VS Lor2/2)
To determine if the VS mutant protein was functioning in
a classical dominant negative fashion, we bred the ML.VS
transgenic mice with loricrin knockout mice (Koch et al.,
2000, this issue). The severity of the ML.VS phenotype
was slightly increased in transgenics that were heterozy-
gous for the wild-type loricrin gene (Lor1/2) compared
with ML.VS transgenics that express both wild-type alleles
(Lor1/1), which was consistent with the mutant protein
functioning as a dominant negative (data not shown). Un-
expectedly, expression of the ML.VS transgene in the lori-
crin null background (Lor2/2) showed a more severe phe-
notype than ML.VS mice in the Lor1/2 background (Fig.
10 a), and as observed previously in the Lor1/1 back-
ground, phenotype severity correlated with transgene dos-
age as evidenced via ML.VS/Lor2/2 sibling matings (Fig.
10 b). Thus, these mating experiments confirm that the VS
mutant protein is not functioning as a classical dominant-
negative molecule, i.e., inducing the phenotype by a direct
interference with wild-type loricrin.
Our initial attempts to examine the distribution of the
VS mutant protein suggested that the VS protein accumu-
lated in the nucleus; however, we could not determine
whether the mutant was also present in the CE, since both
the mutant and wild-type loricrin share the same NH2-ter-
minal epitope. The availability of ML.VS/Lor2/2 mice al-
lowed us to reexamine this question without this complica-
tion. Surprisingly, immunoelectron microscopy revealed
that the VS mutant protein was almost exclusively present
in the nucleus, with little if any incorporation in the CE
(see Fig. 7 c). Thus, the positive labeling with the LorNAb
seen on the cell envelopes of transgenics that also express
wild-type loricrin (see Fig. 7 a, 1/1 mice) presumably only
detects the presence of wild-type loricrin.
The VS Form of Loricrin Contains Several Sequences 
That Meet the Criteria of NLS
A survey of the missense amino acids created by the
frameshift mutation revealed several putative NLS (Ding-
wall and Laskey, 1991; Boulikas, 1993; Valdez et al., 1994)
(Fig. 11 A). To determine whether these sequences were
responsible for the nuclear accumulation of the VS form
of loricrin, the following GFP fusion constructs were trans-
fected into HeLa cells (Fig. 11 B). A vector with a
BamHI–PstI fragment from wild-type loricrin (GFP[ML
BamHI-PstI]) showed a homogenous protein distribution
in the cytoplasm (Fig. 11 C, a). However, a vector with a
BamHI–PstI fragment from the ML.VS transgene
(GFP[ML.VS BamHI-PstI]) showed a patchy or granular
distribution in the nuclei (Fig. 11 C, b). We also con-
structed a vector that contained the COOH-terminal mis-
sense amino acid sequence of ML.VS fused to GFP. The
chimeric protein encoded by this vector also localized to
the nuclei with a patchy or granular distribution (data not
shown), suggesting that nuclear targeting resulted from se-
quences in the COOH terminus of the mutant loricrin pro-
tein. Four arginine-rich sequences within the COOH ter-
minus of ML.VS were identified as possible NLS and
tested in the GFP transfection assay. Only GFP(NLS4)
showed a homogenous distribution inside the nuclei (Fig.
11 C, c). The other candidate sequences, GFP(NLS1–3),
showed a cytoplasmic localization of the GFP fusion pro-
tein (data not shown). Thus, the bipartite NLS(NLS4) is
responsible for the nuclear accumulation of the VS form
of loricrin.
Discussion
To establish a causative relationship between loricrin mu-
tations and the human skin diseases VS and PSEK, we in-
troduced a transgene into the germline of mice containing
a single nucleotide insertion that mimics frameshift muta-
Figure 10. Macroscopic phenotype of ML.VS in the absence of endogenous loricrin (ML.VS Lor2/2). (a) Newborn transgenics without
endogenous loricrin expression seem to have a more scaly and dry skin phenotype than those with endogenous loricrin expression. (b)
ML.VS transgenics that are heterozygous (ML.VS Lor1/2) or homozygous (ML.VS Lor2/2) for the loss of the loricrin gene at day 6.
Note that the phenotype of ML.VS Lor2/2 mice was more severe than that of ML.VS Lor1/2 mice.The Journal of Cell Biology, Volume 151, 2000 410
tions recently identified in VS and PSEK (Maestrini et al.,
1996; Ishida-Yamamoto et al., 1997; Korge et al., 1997;
Armstrong et al., 1998; Takahashi et al., 1999). Newborn
mice expressing this mutant form of loricrin exhibited an
erythematous and shiny skin, which immediately distin-
guished them from their nontransgenic littermates. This
phenotype resembles the erythrokeratoderma observed in
the human disease (Ishida-Yamamoto et al., 1997). Within
the first 4 d after birth, the skin of transgenic neonates be-
came dry and showed ichthyosis-like diffuse scales over
the whole body. This phenotype is of particular interest
since VS is a heterogeneous disease and a recent report
suggests that loricrin mutations are only causative for VS
associated with ichthyosis (Korge et al., 1997). Interest-
ingly, the ichthyotic phenotype gradually disappeared in
founder mice and their F1 progeny, in spite of unchanged
expression of the transgene. We have also observed a
gradual normalization of the congenital erythroderma
phenotype exhibited by loricrin knockout mice (Koch et
al., 2000, this issue). Taken together, these results suggest
the existence of a compensatory mechanism that is in-
duced in an attempt to restore epidermal barrier function.
Increased Expression of the Mutant Transgene Induces 
Additional Phenotypic Changes Similar to Those 
Observed in VS Patients
Since VS is transmitted in an autosomal dominant mode,
we assume that both wild-type and mutant alleles are
equally expressed. In an attempt to more closely mimic
this expression pattern in the mouse model, we generated
mice that were homozygous for the transgene in F2 and
expressed essentially equivalent levels of mutant and wild-
Figure 11. ML.VS loricrin sequence altered GFP localization in
HeLa cells. (A) Comparison of wild-type and mutant COOH-ter-
minal loricrin DNA and amino acid sequence resulting from a
frameshift mutation and delayed termination of translation. The
arrow points to the site of insertion of the point mutation in the
ML.VS construct. Some motifs meeting the criteria of NLS in the
mutant peptide are shown in bold type and underlined (NLS1–b3).
The potential bipartite NLS is boxed, with the relevant basic resi-
dues in bold type (NLS4). (B) Diagram illustrating the subcloning
of sequences from normal and mutant loricrin COOH terminus
into the pEGFP-C vector. BamHI–PstI fragments from wild-type
(a) and mutant loricrin constructs (b), respectively, Acc65I–PstI
fragment (c), and four nuclear targeting motif candidates (d) from
mutant loricrin were fused to the GFP protein. The mutant
COOH terminus is represented by a black box. (C) Subcellular lo-
calization of GFP. GFP plasmids including the various sequences
described above were transfected into HeLa cells. The subcellular
localization of the expressed GFP was analyzed 24 h after transfec-
tion. GFP fluorescence was detected homogeneously in the cyto-
plasm of cells transfected with wild-type loricrin COOH terminus
(a). However, fluorescence was detected in a patchy or granular
pattern in the nuclei of cells transfected with mutant loricrin
COOH terminus plasmid GFP(ML.VS.BamHI-PstI) (b) or
GFP(ML.VS.Acc65I-PstI) (data not shown). GFP(NLS1),
GFP(NLS2), and GFP(NLS3) constructs showed homogeneous
distribution in the cytoplasm (data not shown). Only the NLS4 (bi-
partite NLS) construct was distributed homogeneously in the nu-
clei (c). Nuclei were visualized by staining with DAPI.Suga et al. Transgenic Mice Expressing Mutant Loricrin 411
type transcripts. At birth, homozygous ML.VS mice exhib-
ited a severe erythrokeratoderma that resulted in a four-
fold increase in TEWL compared with controls. The neo-
natal phenotype gradually progressed to a generalized
ichthyosis, and with time, several additional phenotypic
changes occurred that resembled clinical features of VS
patients. Of particular interest was the formation of a con-
stricting band at the base of the tail, similar to that seen
around digits and toes of VS patients. Furthermore, the
footpads developed nonepidermolytic hyperkeratosis.
The constricting band always formed at the base of the
tail. Histologically, this area showed hyperkeratosis with
parakeratosis and increased thickness of the epidermis. It
is possible that this phenotype is due to a higher expres-
sion level of the transgene in the affected area. However,
we did not find an increase in parakeratosis or LorNAb
nuclear staining in sections from the base of the tail com-
pared with the rest of the tail epidermis. It may be that the
thickening of tail epidermis is due not only to expression
of the mutant loricrin, but also to additional factors, such
as mechanical stress, which might be particularly severe at
the tail base. Although the digits of ML.VS mice never de-
veloped pseudoainhum, the footpads did exhibit nonepi-
dermolytic palmoplantar keratoderma (NEPPK), which is
another characteristic feature of VS patients. The molecu-
lar mechanism leading to NEPPK is unclear at present.
However, the susceptibility of palms and soles might also
be due to mechanical stress.
The Phenotype Induced by VS Mutant Loricrin Does 
Not Require a Direct Interaction with
Wild-Type Loricrin
The availability of loricrin knockout mice provided us with
the opportunity to determine whether the VS mutant was
functioning as a classical dominant-negative molecule, i.e.,
was a direct interaction with wild-type loricrin required to
induce the phenotype? It was already evident that the VS
mutant was not simply inactivating wild-type loricrin; oth-
erwise, the VS phenotype would have been identical to the
loss of function phenotype observed in the germline dele-
tion of the loricrin gene, i.e., a mild transient congenital
erythroderma (Koch et al., 2000, this issue). Surprisingly,
we found that the gain of function exhibited by the VS mu-
tant did not require the presence of wild-type loricrin. In
fact, the phenotype was exacerbated in the absence of lori-
crin. This suggests that the mechanisms compensating for
the loss of loricrin (Koch et al., 2000, this issue) are im-
paired in their ability to maintain epidermal barrier func-
tion in the presence of the mutant form of loricrin. We also
used tissue from ML.VS Lor2/2 mice to determine the dis-
tribution of the VS mutant protein. Again to our surprise,
immunoelecton microscopy demonstrated that the VS mu-
tant form of loricrin was almost exclusively present in the
nucleus, with little, if any, incorporation in the CE.
VS Mutant Loricrin Is Localized in the Nucleus and 
Not in the Cell Envelope
Although we cannot entirely exclude preferential masking
of the NH2-terminal epitope on VS mutant loricrin when
cross-linked into the CE, this explanation appears unlikely
since the antibody recognizes this epitope on wild-type
loricrin in the CE and on mutant loricrin in intranuclear
condensates. Moreover, our results are in agreement with
previous observations in studies of the human diseases in
which the same LorNAb was used to analyze clinical sam-
ples from both VS and PSEK patients. Immunoelectron
microscopy revealed that intranuclear granules in the
granular cells and nuclei in parakeratotic cornified cells
were immunoreactive with the LorNAb, whereas the CEs
in these samples were sparsely labeled (Maestrini et al.,
1996; Ishida-Yamamoto et al., 1997). In retrospect, the lat-
ter labeling was probably of wild-type loricrin. Further-
more, to specifically determine the distribution of mu-
tant loricrin in clinical samples, Ishida-Yamamoto et al.
(Ishida-Yamamoto, A., H. Takahashi, and H. Izuka. 1999.
J. Invest. Dermatol. 112:551 [Abstr.]) recently produced
antibodies against a synthetic peptide corresponding to
the sequences unique to the mutant loricrin. Consistent
with the previous results, mutant loricrin was detected in
the nuclei of differentiated epidermal cells and in para-
keratotic nuclei of patient biopsies, but not in the CE.
Assuming that the residues used for cross-linking mu-
rine loricrin into the CE are distributed like those in
human loricrin, which include Lys and Gln residues in
the NH2-terminal and internal non–Gly/Ser-rich domains
(Steinert and Marekov, 1995), the question arises as to
why the VS mutant loricrin, which is identical to wild-type
loricrin in this part of the molecule, is not incorporated
into the CE. Here the putative NLS in its COOH-terminal
domain may provide an answer: it may lead to the mutant
protein being transported efficiently into the nucleus,
thereby preempting the formation of L granules in the cy-
toplasm or direct incorporation into the assembling CE.
Such transport would also account for the large conden-
sates of mutant loricrin that we observe in these nuclei.
How Does the Mutant Form of Loricrin Induce 
Phenotypic Changes in the Epidermis?
As discussed above, our mating experiments with the lori-
crin knockout mice establish that the phenotypes elicited
by the mutant do not require the presence of wild-type
loricrin. Furthermore, the immunoelectron microscopic
data indicate that the mutant loricrin does not enter into
the CE, but is mainly, if not exclusively, in the nucleus. Ul-
trastructurally, the CEs of ML.VS mice look normal. Since
loricrin knockout mice assemble CEs of the usual thick-
ness and uniformity, using other proteins as building
blocks (Jarnik et al., manuscript submitted for publica-
tion), it appears likely that similar adaptations take place
in the epidermis of ML.VS mice. Although it remains pos-
sible that the mutant loricrin may somehow interfere indi-
rectly with CE assembly, there are no strong indications
that this is the case because adequate CEs appear to be as-
sembled in either a 1/2 or a 2/2 background. Thus, the
VS-related phenotypes appear to result not from a defec-
tive CE, but from expression of the mutant loricrin, which
then accumulates in the nucleus of cells in the granular
layer.
This phenomenon may be responsible for disrupting the
process whereby the nucleus is normally broken down
during maturation of granular layer cells to corneocytes so
that parakeratotic cells are found in the stratum corneum.
The presence of parakeratotic cells may interrupt the or-
derly deposition of flattened squames and the cohesive-The Journal of Cell Biology, Volume 151, 2000 412
ness of the stratum corneum. This simplistic mechanism
could contribute both to the observed defect in permeabil-
ity barrier and to the ichthyotic phenotype. However, it
does not account for pseudoainhum in an evident way,
suggesting that the late stages of epidermal differentiation
are perturbed in a more global manner. In future studies,
it may be possible to elucidate these mechanisms further
by preventing nuclear accumulation of the VS mutant
through selective alterations in the putative nuclear local-
ization sequence in the substituted COOH terminus of the
mutant loricrin.
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